Claudia Riedl

Ventaleon GmbH is a biotechnology company, which engages in the development of inhaled treatments against viral infections. Its products include LASAG (D,L-lysine acetylsalicylate • glycine), a lysin-salt formulation of well known acetyl salicylic acid. The company was founded by Gerhard Scheuch in 2012 and is headquartered in Gauting, Germany.

Vectura GmbH manufactures and develops pharmaceutical therapies for airways diseases. It offers dry powder formulation technology, device technology, and development capabilities. The company was founded by Gerhard Scheuch in 1997 and is headquartered in Gemünden, Germany.

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

Market Logic Software AG designs and develops enterprise business software for product management. Its software helps to manage research, search information, build knowledge, guide innovation, plan marketing and drive sales. The firm provides marketing information systems to the marketing and research teams. Its clients include global brands from FMCG and CPG, healthcare, retail, high-tech, finance and communications sectors and research agencies. The company was founded by Kay Iversen in 2006 and is headquartered in Berlin, Germany.

ProBioGen AG operates as a contract development and manufacturing organization. It specializes in cell line engineering, process development, and GMP manufacturing of biopharmaceuticals. The firm offers services such as cell line development, process development, manufacturing programs, physio-chemical analyses, and cell-based assays. The company was founded by Uwe Marx on June 13, 1994 and is headquartered in Berlin, Germany.

CODIXX AG specializes in the production, development, and distribution of glass polarizers. It encompasses visible and infrared standard, ultraviolet, and high-transmittance polarizers. The company was founded on September 1, 1998 and is headquartered in Barleben, Germany.

Beteiligungsgesellschaft Sachsen-Anhalt mbH is a private equity/ venture capital firm founded in 1996. The firm is headquartered in Magedeburg.

Scienion AG develops and provides DNA biochips and protein microarrays. It provides its customers in the pharmaceutical, biotech, diagnostic and reagent supply markets, as well as in academic research institutions with products, and services to facilitate confidence and efficiency in aspects of its applications. The company was founded by Holger Eickhoff in 2000 and is headquartered in Dortmund, Germany.

LSP Management Group BV (LSP) is an independent European venture capital firm which was founded by Martijn Kleijwegt, Frits van der Have and Tom Schwarz in 1998. Headquartered in Amsterdam, the firm provides financing to early- to mid-stage life science companies.

IDEA AG develops pain therapeutics and biopharmaceutical drugs. The firm develops and commercializes non-invasive therapeutic drugs and the targeted pain therapeutics for arthritic and osteoporosis-related inflammation, chronic pain and diseases. Its technology platform is based on proprietary carriers applied on skin and engineered to diminish side effects and increase drug potency. The company founded by Gregor Cevc in 1993 and is headquartered in Munich, Germany.

Curexsys GmbH is a German company founded by molecular biologist Jens Gruber and biochemist Dr. Herbert Stadler. The company is based in Goettingen, Germany. The company aims to become a leading supplier for clinical grade exosomes in regenerative medicine and anti-aging therapies. Exosomes are extracellular, nanoscale vesicles that transfer information to neighboring cells and distant tissues. Curexsys is currently pursuing the development of several programs in three indications, focusing on the generation of clearly defined, characterized, and purified extracellular vesicles/exosomes from their proprietary iMSC lines derived from Evotec's iPSC platform.

ImCyse SA engages in the development of curative therapies in the field of immune and allergic pathologies. It offers a technological platform that helps develop medicinal products with potential benefits in all clinical circumstances where HLA class II restricted specific immunity can be causative of or contribute to damages to humans or animals. The firm's products are used in organ-specific autoimmunity, allergy, alloimmunity, cancer and infectious diseases. The company was founded in August 2010 by Jean-Marie R. Saint-Remy and is headquartered in Liege, Belgium.

Elector GmbH engages in the acquisition, holding, and management of participating interests in firms. The company was founded on November 20, 2012 and is headquartered in Berlin, Germany.

MedNet GmbH provides standard and customized components for medical devices and other industries from a single source. The private company is based in Muenster, Germany. The CEOs are David Thaler, Inge Bröskamp. The German company was founded in 1990.

Merck Serono SA operates as a holding company in the pharmaceutical field. It engages in the research, development, manufacture, and distribution of therapeutic products for the treatment of human diseases. The company was founded on May 21, 1987 and is headquartered in Coinsins, Switzerland.

Crelux GmbH provides structure based drug discovery solutions. The firm provides customized services to support hit-finding, conformational analysis and lead optimization, including protein production, biophysical assays, fragment screening, and X-ray crystallography. It works for pharma, biotech and research organizations. The company was founded by Ismail Moarefi, Martin Ried and Michael Schaeffer and is headquartered in Martinsried, Germany.

Immunic AG develops pharmaceuticals in the immunology space. The firm offers immune modulators to block TH17-and TH1-mediated immune and autoimmune responses. The company was founded by Andreas Muhler and Manfred Groppel in April 2016 and is headquartered in Martinsried, Germany.

Franklin Templeton Investment Management Ltd. (Germany) (FTIML-Germany) is the German investment management division of Great Britain-based Franklin Templeton Investment Management Ltd., ultimately owned by Franklin Resources, Inc. (NYSE: BEN) in the US. Headquartered in Frankfurt, the firm was founded in 1992 and manages the Franklin Templeton Investments fund range for individuals, pension funds, trusts, local authorities, corporations, government bodies, fund of funds and multi-managers.

Creathor Venture Management GmbH is an independent private equity firm specialized in technology venture capital investing. Creathor was foundedi n 2003 and is headquartered in Bad Homburg near Frankfurt in central Germany. The management invests their own capital, and manages venture capital funds on behalf of institutions.

Atriva Therapeutics GmbH is a biopharmaceutical company that develops host-targeting antiviral therapies. It focuses on the development of new antiviral therapies against different respiratory viral infections. The company was founded by Rainer Lichtenberger and Henrik Luer Lueßen in April 2015 and is headquartered in Tuebingen, Germany.

OMEICOS Therapeutics GmbH develops small molecules using endogenous protective mechanism for the treatment and prevention of atrial fibrillation. It operates as a biopharmaceutical company developing molecule therapeutics for the prevention and treatment of cardiovascular diseases including atrial fibrillation. The company was founded by Wolf-Hagen Schunck, John R. Falck, Dominik Müller, Robert Fischer and Karen Uhlmann in 2013 and is headquartered in Berlin, Germany.